RU2016136504A - ПРИМЕНЕНИЕ ЭРИБУЛИНА И ИНГИБИТОРОВ mTOR В КАЧЕСТВЕ КОМБИНИРОВАННОЙ ТЕРАПИИ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ - Google Patents
ПРИМЕНЕНИЕ ЭРИБУЛИНА И ИНГИБИТОРОВ mTOR В КАЧЕСТВЕ КОМБИНИРОВАННОЙ ТЕРАПИИ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ Download PDFInfo
- Publication number
- RU2016136504A RU2016136504A RU2016136504A RU2016136504A RU2016136504A RU 2016136504 A RU2016136504 A RU 2016136504A RU 2016136504 A RU2016136504 A RU 2016136504A RU 2016136504 A RU2016136504 A RU 2016136504A RU 2016136504 A RU2016136504 A RU 2016136504A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- eribulin
- solvate
- hydrate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461947398P | 2014-03-03 | 2014-03-03 | |
| US61/947,398 | 2014-03-03 | ||
| PCT/US2015/018335 WO2015134399A1 (en) | 2014-03-03 | 2015-03-02 | Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016136504A true RU2016136504A (ru) | 2018-04-03 |
| RU2016136504A3 RU2016136504A3 (cg-RX-API-DMAC7.html) | 2018-10-25 |
Family
ID=54055761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016136504A RU2016136504A (ru) | 2014-03-03 | 2015-03-02 | ПРИМЕНЕНИЕ ЭРИБУЛИНА И ИНГИБИТОРОВ mTOR В КАЧЕСТВЕ КОМБИНИРОВАННОЙ ТЕРАПИИ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20170071903A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3113775A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2017507151A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20160135230A (cg-RX-API-DMAC7.html) |
| CN (1) | CN106029070A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015225436A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2940983A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL247586A0 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2016136504A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201607298QA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015134399A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5226304B2 (ja) | 2004-06-03 | 2013-07-03 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ハリコンドリンｂ類似体の調製用中間体 |
| PT2415470T (pt) | 2009-03-30 | 2016-08-31 | Eisai R&D Man Co Ltd | Composição de lipossomas |
| WO2014208774A1 (en) | 2013-06-26 | 2014-12-31 | Eisai R&D Management Co., Ltd. | Use of eribulin and lenvatinib as combination therapy for treatment of cancer |
| EP3449921B1 (en) * | 2016-04-28 | 2023-05-31 | Eisai R&D Management Co., Ltd. | Eribulin for inhibiting tumor growth |
| EP3713565A1 (en) | 2017-11-20 | 2020-09-30 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| CN113271977A (zh) * | 2018-11-09 | 2021-08-17 | G1治疗公司 | 使用艾日布林和选择性cdk4/6抑制剂组合治疗癌症的治疗方案 |
| US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140019032A (ko) * | 2006-04-05 | 2014-02-13 | 노파르티스 아게 | 암을 치료하기 위한 치료제의 조합물 |
| NZ598489A (en) * | 2009-08-27 | 2014-03-28 | Bionomics Ltd | Combination therapy for treating proliferative diseases |
| EP2680839A1 (en) * | 2011-03-02 | 2014-01-08 | Morphotek, Inc. | Co -administration of eribulin and farletuzumab for the treatment of breast cancer |
| US20150231219A1 (en) * | 2012-04-02 | 2015-08-20 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of monospecific and bispecific anti-igr-1r and anti-erbb3 antibodies |
-
2015
- 2015-03-02 CN CN201580011593.4A patent/CN106029070A/zh active Pending
- 2015-03-02 KR KR1020167027369A patent/KR20160135230A/ko not_active Withdrawn
- 2015-03-02 EP EP15758504.3A patent/EP3113775A4/en not_active Withdrawn
- 2015-03-02 RU RU2016136504A patent/RU2016136504A/ru unknown
- 2015-03-02 JP JP2016555458A patent/JP2017507151A/ja active Pending
- 2015-03-02 AU AU2015225436A patent/AU2015225436A1/en not_active Abandoned
- 2015-03-02 CA CA2940983A patent/CA2940983A1/en not_active Abandoned
- 2015-03-02 SG SG11201607298QA patent/SG11201607298QA/en unknown
- 2015-03-02 WO PCT/US2015/018335 patent/WO2015134399A1/en not_active Ceased
- 2015-03-02 US US15/123,476 patent/US20170071903A1/en not_active Abandoned
-
2016
- 2016-08-31 IL IL247586A patent/IL247586A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3113775A1 (en) | 2017-01-11 |
| CA2940983A1 (en) | 2015-09-11 |
| JP2017507151A (ja) | 2017-03-16 |
| RU2016136504A3 (cg-RX-API-DMAC7.html) | 2018-10-25 |
| AU2015225436A1 (en) | 2016-09-08 |
| WO2015134399A1 (en) | 2015-09-11 |
| CN106029070A (zh) | 2016-10-12 |
| KR20160135230A (ko) | 2016-11-25 |
| IL247586A0 (en) | 2016-11-30 |
| US20170071903A1 (en) | 2017-03-16 |
| EP3113775A4 (en) | 2017-08-23 |
| SG11201607298QA (en) | 2016-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016136504A (ru) | ПРИМЕНЕНИЕ ЭРИБУЛИНА И ИНГИБИТОРОВ mTOR В КАЧЕСТВЕ КОМБИНИРОВАННОЙ ТЕРАПИИ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ | |
| Iglesias et al. | Drug resistance in non-small cell lung cancer: a potential for NOTCH targeting? | |
| Wang et al. | Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer | |
| JP2017507151A5 (cg-RX-API-DMAC7.html) | ||
| JP2016528162A5 (cg-RX-API-DMAC7.html) | ||
| JP6620338B2 (ja) | 低用量ナルトレキソンによるがん細胞の準備刺激 | |
| JP2011515397A5 (cg-RX-API-DMAC7.html) | ||
| JP7530116B2 (ja) | エムトール信号伝達抑制剤を有効成分として含む癌の予防又は治療用薬剤学的組成物 | |
| Jia et al. | Artesunate ameliorates irinotecan-induced intestinal injury by suppressing cellular senescence and significantly enhances anti-tumor activity | |
| RU2017134148A (ru) | Комбинация тасквинимода или его фармацевтически приемлемой соли и ингибитора pd-1 и/или pd-l1 для применения в качестве лекарственного средства | |
| RU2016151303A (ru) | Применение эрибулина в лечении рака | |
| Hou et al. | Autophagy and tumour chemotherapy | |
| JP6997919B2 (ja) | がんの処置のためのトランス－［テトラクロロビス（１ｈ－インダゾール）ルテネート（ｉｉｉ）］の使用 | |
| Ding et al. | SAHA triggered MET activation contributes to SAHA tolerance in solid cancer cells | |
| JP2019511553A (ja) | 静止細胞標的化および有糸分裂の阻害剤を用いた新生物の処置のための組み合わせ | |
| Liao et al. | RETRACTED: Combination of Tanshinone IIA and Cisplatin Inhibits Esophageal Cancer by Downregulating NF-κB/COX-2/VEGF Pathway | |
| Su et al. | Cepharanthine hydrochloride inhibits the Wnt/β-catenin/Hedgehog signaling axis in liver cancer | |
| JP2019513812A5 (cg-RX-API-DMAC7.html) | ||
| Selvaggi et al. | Wingless/It/β-catenin signaling in liver metastasis from colorectal cancer: A focus on biological mechanisms and therapeutic opportunities | |
| Mountzios et al. | Novel Approaches for Concurrent Irradiation in Locally Advanced Cervical Cancer: Platinum Combinations, Non‐Platinum‐Containing Regimens, and Molecular Targeted Agents | |
| Torki et al. | Synergistic antitumor effect of NVP-BEZ235 and CAPE on MDA-MB-231 breast cancer cells | |
| Chen et al. | The antipancreatic cancer activity of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2 | |
| RU2012148706A (ru) | Комбинация органичемких соединений | |
| WO2019017497A1 (en) | USE OF CYCLIN-DEPENDENT KINASE ERIBULINE AND INHIBITORS IN THE TREATMENT OF CANCER | |
| JP7468829B2 (ja) | 癌を処置するための、癌治療剤と組み合わせたＩＲＥ１α阻害剤 |